The present invention relates to apertured pouches comprising a fibrous matrix containing a cannabinoid and/or terpene ingredient, including kits, methods of use and methods of manufacture.

Compositions for development of matrix type extended release mesalamine minitablets without use of any modified release coating, comprising a) mesalamine or its prodrug or derivatives thereof having a weight percentage in a range of 65-85 weight percentage with respect to the composition; b) at least one intragranular excipient having a weight percentage in a range of 3.5-22.5 weight percentage with respect to the composition; c) at least one binder having a weight percentage in a range of 2-6.5 weight percent with respect to the composition; and d) at least one extra granular excipient having a weight percentage in a range of 2-5 weight percentage with respect to the composition such that largest dimension in the minitablet is range of 1.00 mm to 2.8 mm. In another aspect of the present disclosure provides for a process of preparation of composition.

The present invention relates to dissolvable containers for animal feed micro-ingredients, and methods for using such dissolvable containers to prepare an animal feed mixture. Ingredients required in very small amounts with respect to the rest of the components in an animal feed, i.e., micro-ingredients, can be pre-measured and sealed within the dissolvable containers, which can be made from a water-soluble polymer film, then added to the other feed components when the complete animal feed is being prepared.

A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.

##STR00001##

A single-dose composition and related kits and methods, including powder mannitol at an amount from 50 to 200 grams, wherein the powder mannitol has a bulk density ranging from 0.4 g/ml to 0.65 g/ml is described. A percentage ranging from 90% to 100% by weight of the particles of powder mannitol has a particle size distribution ranging from 1 μm to 500 μm.

An oral pouch product includes a wrapper and a filling material. The wrapper defines a cavity. The filling material is in the cavity. The filling material includes a dry mixture and a liquid mixture. The dry mixture includes a cellulosic material and a water-soluble filler. The liquid mixture includes an oil and liquid nicotine. The oil includes a triglyceride, a diglyceride, a monoglyceride, or any combination thereof. The liquid nicotine is dissolved in the oil. The filling material is free of water or includes water in an amount less than or equal to 5 weight percent.

A solid composition with rapid ingestion and facilitated swallowing, in the form of non-agglomerated solid particles, said composition comprising the following two different types of particle: Pa particles, with very low solubility in saliva and comprising at least one active ingredient, and Ps particles, rapidly soluble in saliva, characterised by an apparent density equal to or greater than approximately 0.6 g.cm.sup.−3, advantageously equal to or greater than approximately 0.7 g.cm.sup.−3, and preferably between 0.7 and 1.5 g.cm.sup.−3 inclusive.

The present invention relates to a pouch product suitable for application in an oral cavity of a human comprising a sealable pouch material containing a filling material comprising i) 0 to 10 wt % Cannabis, ii) 0 to 10 wt % nicotine, whereby nicotine is present in the form of iia) tobacco or iib) as nicotine pure and as nicotine salicylic acid salt at a ratio of pure to salt of 0.20-1:1, 5 and up to of one or more 100 wt % of iii) a sweetener, iv) a pH regulator, and optionally v) essential oil as taste agent. The filling material further comprises vi) up to 76 wt % of a filler consisting of vi-1) 42 to 60 wt % microcrystalline cellulose and vi-2) 11 to 22 wt % potato fibers, at a ratio of 2.0-5:1, and vii) 0.1 to 5 wt % of xanthan gum as a wetting agent, whereby the ratio between microcrystalline cellulose, potato fibers and xanthan gum is 1.0-5:1:0.001-0.4. 10

The present invention relates to a pharmaceutical composition comprising a combination of mirabegron and solifenacin or their pharmaceutically acceptable salts, wherein the composition comprises mini-tablets, multiparticulates, inlay tablets, or bilayer tablets. The prior art discloses restrictive formulation techniques and suggests complexity for preparing the combination in a single formulation to achieve the desired technical attributes. The test formulations are stable and exhibit desired pharmaceutical technical attributes. The invention also relates to the use of the pharmaceutical composition of the present invention in the treatment of various diseases like overactive bladder and other related therapeutic indications.

An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.